Literature DB >> 11104577

Anti-CD7 antibody and immunotoxin treatment of human CD7(+)T-cell leukaemia is significantly less effective in NOD/LtSz-scid mice than in CB.17 scid mice.

D J Flavell1, S L Warnes, A L Noss, S U Flavell.   

Abstract

Groups of 8 to ten SCID (CB.17 scid/scid) or NOD/SCID (NOD/LtSz- scid/scid) mice were injected i.v. with two million human HSB-2 T-ALL cells on day 1 (SCID-HSB-2 and NOD/SCID-HSB-2 mice) and treated later with 3 i.v. 10 microg doses of the anti-CD7 antibody HB2 on days 7, 9 and 11 or with a single 10 microg dose of HB2-SAPORIN or a 7.4 microg dose of HB2-F(ab)(2)-SAPORIN immunotoxin (IT) on day 7. Treatment of SCID-HSB-2 mice with HB2-SAPORIN led to a significant prolongation in the time to development of signs and symptoms of disease compared with PBS sham-treated controls with 80% of animals surviving disease-free. In contrast treatment with HB2-F(ab)(2)-SAPORIN was significantly less effective in SCID-HSB-2 mice with 80% of animals in this treatment group developing leukaemia over the course of the study. HB2 antibody treatment of SCID-HSB-2 mice also led to a significant prolongation in time to leukaemia development compared with sham-treated controls with 37% of animals in this treatment group disease-free at termination of the study. In contrast HB2 antibody treatment of NOD/SCID-HSB-2 mice had no therapeutic effect in these animals and the therapeutic effectiveness of both HB2-SAPORIN and HB2-F(ab)(2)-SAPORIN ITs was similar and significantly reduced compared to the effect observed in SCID-HSB-2 mice. It was initially thought that the lack of therapeutic effect of antibody and IT in NOD-SCID-HSB-2 mice might relate to their putative lack of NK cells but flow cytometric and functional studies with NOD-SCID mouse splenocytes revealed that these animals do have some functional NK cells though fewer in number and possibly lower in functionality than those of SCID mice. We reason that the complete lack of therapeutic effect of HB2 antibody and the reduced effect of HB2-SAPORIN in NOD/SCID mice is due to the reduced cytolytic activity of NOD/SCID NK cells which is probably below a certain critical threshold value in these animals. We conclude from this that immunotherapeutics like HB2-SAPORIN would be more accurately assessed for intrinsic potency in NOD/SCID mice where the effects of NK cell and possibly other non-adaptive immune mechanisms would not have a significant influence. Copyright 2000 Cancer Research Campaign.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11104577      PMCID: PMC2363443          DOI: 10.1054/bjoc.2000.1565

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  28 in total

1.  Host-mediated antibody-dependent cellular cytotoxicity contributes to the in vivo therapeutic efficacy of an anti-CD7-saporin immunotoxin in a severe combined immunodeficient mouse model of human T-cell acute lymphoblastic leukemia.

Authors:  D J Flavell; S Warnes; A Noss; S U Flavell
Journal:  Cancer Res       Date:  1998-12-15       Impact factor: 12.701

2.  Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice.

Authors:  L M Pilarski; G Hipperson; K Seeberger; E Pruski; R W Coupland; A R Belch
Journal:  Blood       Date:  2000-02-01       Impact factor: 22.113

3.  Progressive loss of H-2 antigens with concomitant increase of cell-surface antigen(s) determined by Moloney leukemia virus in cultured murine lymphomas.

Authors:  M Cikes; S Friberg; G Klein
Journal:  J Natl Cancer Inst       Date:  1973-02       Impact factor: 13.506

4.  Immunologic aspects of the nonobese diabetic (NOD) mouse. Abnormalities of cellular immunity.

Authors:  S Kataoka; J Satoh; H Fujiya; T Toyota; R Suzuki; K Itoh; K Kumagai
Journal:  Diabetes       Date:  1983-03       Impact factor: 9.461

5.  A severe combined immunodeficiency mutation in the mouse.

Authors:  G C Bosma; R P Custer; M J Bosma
Journal:  Nature       Date:  1983-02-10       Impact factor: 49.962

6.  Severe combined immunodeficiency (SCID) in the mouse. Pathology, reconstitution, neoplasms.

Authors:  R P Custer; G C Bosma; M J Bosma
Journal:  Am J Pathol       Date:  1985-09       Impact factor: 4.307

7.  An immunotoxin composed of monoclonal anti-Thy 1.1 antibody and a ribosome-inactivating protein from Saponaria officinalis: potent antitumor effects in vitro and in vivo.

Authors:  P E Thorpe; A N Brown; J A Bremner; B M Foxwell; F Stirpe
Journal:  J Natl Cancer Inst       Date:  1985-07       Impact factor: 13.506

8.  Functional status of cells from lymphoid and myeloid tissues in mice with severe combined immunodeficiency disease.

Authors:  K Dorshkind; G M Keller; R A Phillips; R G Miller; G C Bosma; M O'Toole; M J Bosma
Journal:  J Immunol       Date:  1984-04       Impact factor: 5.422

9.  Natural killer (NK) cells are present in mice with severe combined immunodeficiency (scid).

Authors:  K Dorshkind; S B Pollack; M J Bosma; R A Phillips
Journal:  J Immunol       Date:  1985-06       Impact factor: 5.422

10.  Defective activation of T suppressor cell function in nonobese diabetic mice. Potential relation to cytokine deficiencies.

Authors:  D V Serreze; E H Leiter
Journal:  J Immunol       Date:  1988-06-01       Impact factor: 5.422

View more
  7 in total

Review 1.  Immunotoxins and other conjugates containing saporin-s6 for cancer therapy.

Authors:  Letizia Polito; Massimo Bortolotti; Manuela Pedrazzi; Andrea Bolognesi
Journal:  Toxins (Basel)       Date:  2011-06-22       Impact factor: 4.546

2.  Nilotinib and imatinib are comparably effective in reducing growth of human eosinophil leukemia cells in a newly established xenograft model.

Authors:  Daniel Wicklein; Nuno Ramos Leal; Johannes Salamon; Mohammed Thamer; Harald Herrmann; Peter Valent; Udo Schumacher; Sebastian Ullrich
Journal:  PLoS One       Date:  2012-02-14       Impact factor: 3.240

Review 3.  Strategies to Improve the Clinical Utility of Saporin-Based Targeted Toxins.

Authors:  Francesco Giansanti; David J Flavell; Francesco Angelucci; Maria Serena Fabbrini; Rodolfo Ippoliti
Journal:  Toxins (Basel)       Date:  2018-02-13       Impact factor: 4.546

4.  A cascade targeting strategy based on modified bacterial vesicles for enhancing cancer immunotherapy.

Authors:  Yuewen Zhai; Yuying Ma; Bo Pang; Jinnan Zhang; Ying Li; Yalan Rui; Tian Xu; Yu Zhao; Zhiyu Qian; Yueqing Gu; Siwen Li
Journal:  J Nanobiotechnology       Date:  2021-12-20       Impact factor: 10.435

5.  Reevaluation of NOD/SCID Mice as NK Cell-Deficient Models.

Authors:  Miao Miao; Henry Masengere; Guang Yu; Fengping Shan
Journal:  Biomed Res Int       Date:  2021-11-10       Impact factor: 3.411

Review 6.  Saporin-S6: a useful tool in cancer therapy.

Authors:  Letizia Polito; Massimo Bortolotti; Daniele Mercatelli; Maria Giulia Battelli; Andrea Bolognesi
Journal:  Toxins (Basel)       Date:  2013-10-07       Impact factor: 4.546

Review 7.  Engineering of Ribosome-inactivating Proteins for Improving Pharmacological Properties.

Authors:  Jia-Qi Lu; Zhen-Ning Zhu; Yong-Tang Zheng; Pang-Chui Shaw
Journal:  Toxins (Basel)       Date:  2020-03-09       Impact factor: 4.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.